In contrast, in people with type 2 diabetes, it raised fasting glucagon concentrations (7.9 ± 0.3 nmol/L versus 10.2 ± 0.3 nmol/L, P < 0.01 [Figure 2F]) as well as nadir concentrations (6.8 ± 0.6 nmol/L versus 4.1 ± 0.4 nmol/L, P < 0.01) during the hyperglycemic clamp. The gene discussed is GCG; the disease is type 2 diabetes mellitus.